U.S. markets open in 7 hours 41 minutes

Graybug Vision, Inc. (GRAY)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.6030-0.0231 (-3.69%)
At close: 03:59PM EST

Graybug Vision, Inc.

203 Redwood Shores Parkway
Suite 620
Redwood City, CA 94065
United States
650 487 2800

Full Time Employees13

Key Executives

NameTitlePayExercisedYear Born
Dr. Frederic Guerard Pharm.D.Pres, CEO, Sec. & Director931.02kN/A1973
Mr. Robert S. BreuilCFO & Treasurer577.47kN/A1962
Dr. Gerald D. Cagle Ph.D.Sr. Advisor & Head of Bus. Devel.44.67kN/A1944
Dr. Parisa Zamiri M.D., Ph.D.Chief Medical Officer662.11kN/A1965
Dr. Peter A. Campochiaro M.D.Co-FounderN/AN/AN/A
Dr. Peter J. McDonnell M.D.Co-FounderN/AN/A1959
Ms. Bettina MaunzChief People Officer & Head of CommunicationsN/AN/AN/A
Mr. Ming YangSr. VP of R&DN/AN/AN/A
Dr. Ward M. Peterson Ph.D.Sr. VP of Preclinical Devel.N/AN/AN/A
Mr. Ali Kakavand Ph.D.VP & Head of Program ManagementN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.

Corporate Governance

Graybug Vision, Inc.’s ISS Governance QualityScore as of December 1, 2022 is 7. The pillar scores are Audit: 7; Board: 5; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.